|
US5183884A
(en)
|
1989-12-01 |
1993-02-02 |
United States Of America |
Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
|
|
US6657103B1
(en)
|
1990-01-12 |
2003-12-02 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5344760A
(en)
|
1991-06-03 |
1994-09-06 |
Ciba Corning Diagnostics Corp. |
Method of cancer detection
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US6983227B1
(en)
|
1995-01-17 |
2006-01-03 |
Intertech Ventures, Ltd. |
Virtual models of complex systems
|
|
DE69638269D1
(de)
|
1995-06-14 |
2010-11-18 |
Univ California |
Hochaffine humane antikörper gegen tumorantigene
|
|
AU727082B2
(en)
|
1996-03-27 |
2000-11-30 |
Genentech Inc. |
ErbB3 antibodies
|
|
US5968511A
(en)
|
1996-03-27 |
1999-10-19 |
Genentech, Inc. |
ErbB3 antibodies
|
|
WO1998002540A1
(en)
|
1996-07-12 |
1998-01-22 |
Genentech, Inc. |
Chimeric heteromultimer adhesins
|
|
US6255455B1
(en)
|
1996-10-11 |
2001-07-03 |
The Trustees Of The University Of Pennsylvania |
Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
|
|
US20020002276A1
(en)
|
1997-02-10 |
2002-01-03 |
Genentech, Inc. |
Chimeric heteromultimer adhesins
|
|
US6417168B1
(en)
|
1998-03-04 |
2002-07-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of treating tumors
|
|
GB2336695A
(en)
|
1998-04-20 |
1999-10-27 |
Teamware Group Oy |
Modelling a work process
|
|
WO1999060023A1
(en)
|
1998-05-15 |
1999-11-25 |
Imclone Systems Incorporated |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
|
|
AUPQ105799A0
(en)
|
1999-06-18 |
1999-07-08 |
Victor Chang Cardiac Research Institute, The |
Cell growth inhibition
|
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
PL202369B1
(pl)
|
1999-08-27 |
2009-06-30 |
Genentech Inc |
Zastosowanie przeciwciała skierowanego przeciw ErbB2, zastosowanie przeciwciała skierowanego przeciw ErbB oraz zestaw zawierający to przeciwciało
|
|
US7390632B2
(en)
|
1999-09-30 |
2008-06-24 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 receptor isoforms
|
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
JP2003530130A
(ja)
|
2000-04-14 |
2003-10-14 |
メタボロン インコーポレイテッド |
メタボロミクスを使用した薬物発見、疾患の処置、及び診断のための方法
|
|
CN1447696A
(zh)
|
2000-05-19 |
2003-10-08 |
杰南技术公司 |
用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
|
|
US20020119148A1
(en)
|
2000-09-01 |
2002-08-29 |
Gerritsen Mary E. |
ErbB4 antagonists
|
|
US6871171B1
(en)
|
2000-10-19 |
2005-03-22 |
Optimata Ltd. |
System and methods for optimized drug delivery and progression of diseased and normal cells
|
|
EP1228766A1
(en)
|
2001-01-31 |
2002-08-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
PYK2 phosphorylation by HER3 induces tumor invasion
|
|
US7589180B2
(en)
*
|
2001-05-11 |
2009-09-15 |
Abbott Laboratories Inc. |
Specific binding proteins and uses thereof
|
|
US7612042B2
(en)
|
2001-05-31 |
2009-11-03 |
Tumor Biology Investment Group, Inc. |
Methods for inhibiting heregulin and treating cancer
|
|
US7125680B2
(en)
|
2001-07-27 |
2006-10-24 |
The Regents Of The University Of California |
Methods and materials for characterizing and modulating interaction between heregulin and HER3
|
|
US20040248196A1
(en)
|
2001-08-03 |
2004-12-09 |
Adams Timothy Edward |
Methods of screening based on the egf receptor crystal structure
|
|
AU2002326531A1
(en)
|
2001-08-03 |
2003-02-17 |
The Trustees Of The University Of Pennsylvania |
Monoclonal antibodies to activated erbb family members and methods of use thereof
|
|
EP1283053A1
(en)
|
2001-08-09 |
2003-02-12 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Inhibitors of HER3 activity
|
|
KR20050038578A
(ko)
|
2001-10-19 |
2005-04-27 |
파르마 마르, 에스.에이. |
항종양성 화합물의 암치료에 있어서의 향상된 용도
|
|
US7415359B2
(en)
|
2001-11-02 |
2008-08-19 |
Gene Network Sciences, Inc. |
Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents
|
|
US7919098B2
(en)
|
2002-03-26 |
2011-04-05 |
Zensun ( Shanghai ) Sci & Tech Co., Ltd. |
ErbB-3 based methods and compositions for treating neoplasms
|
|
US7332585B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
US20040248151A1
(en)
|
2002-04-05 |
2004-12-09 |
Ventana Medical Systems, Inc. |
Method for predicting the response to HER2-directed therapy
|
|
US7332580B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The University Of California |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
US20040229380A1
(en)
|
2002-05-21 |
2004-11-18 |
Po-Ying Chan-Hui |
ErbB heterodimers as biomarkers
|
|
WO2004000102A2
(en)
|
2002-06-19 |
2003-12-31 |
Abgenix, Inc. |
Method for predicting response to epidermal growth factor receptor-directed therapy
|
|
EP1600459A3
(en)
|
2002-06-28 |
2005-12-07 |
Domantis Limited |
Ligand
|
|
AU2003302821B2
(en)
|
2002-12-11 |
2009-05-07 |
Cell Signaling Technology, Inc. |
Method for predicting the response to HER2-directed therapy
|
|
EP1613732A4
(en)
|
2003-04-01 |
2012-03-14 |
Monogram Biosciences Inc |
INTRA-CELLULAR COMPLEXES AS BIOMARKERS
|
|
US20050079184A1
(en)
|
2003-08-08 |
2005-04-14 |
Immunomedics, Inc. |
Bispecific antibodies for inducing apoptosis of tumor and diseased cells
|
|
WO2005017493A2
(en)
|
2003-08-15 |
2005-02-24 |
Smithkline Beecham Corporation |
Biomarkers in cancer
|
|
US8554486B2
(en)
|
2004-02-20 |
2013-10-08 |
The Mathworks, Inc. |
Method, computer program product, and apparatus for selective memory restoration of a simulation
|
|
EP3611273A1
(en)
|
2004-03-31 |
2020-02-19 |
The General Hospital Corporation |
Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
|
|
AU2005249396B2
(en)
|
2004-05-05 |
2011-10-20 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents for modulating biological activity
|
|
EP2527460B1
(en)
|
2004-05-27 |
2014-12-24 |
The Regents of The University of Colorado |
Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
|
|
US7794960B2
(en)
|
2004-06-04 |
2010-09-14 |
Glaxosmithkline Llc |
Predictive biomarkers in cancer therapy
|
|
JP2008515774A
(ja)
|
2004-08-03 |
2008-05-15 |
ダイアックス コーポレイション |
ｈＫ１結合タンパク質
|
|
RU2410438C2
(ru)
|
2004-08-06 |
2011-01-27 |
Дженентек, Инк. |
Анализы и способы, использующие биомаркеры
|
|
CA2576886A1
(en)
|
2004-08-12 |
2006-02-23 |
Dyax Corp. |
Tie complex binding proteins
|
|
US20060136139A1
(en)
|
2004-10-12 |
2006-06-22 |
Elcock Adrian H |
Rapid computational identification of targets
|
|
WO2006044748A2
(en)
|
2004-10-15 |
2006-04-27 |
Monogram Biosciences, Inc. |
RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
|
|
ZA200704796B
(en)
|
2004-12-07 |
2008-11-26 |
Genentech Inc |
Selecting patients for therapy with a HER inhibitor
|
|
US7862995B2
(en)
|
2004-12-10 |
2011-01-04 |
Targeted Molecular Diagnostics |
Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
|
|
JP2008531557A
(ja)
|
2005-02-23 |
2008-08-14 |
メリマック ファーマシューティカルズ インコーポレーティッド |
生物活性を調節するための二重特異性結合剤
|
|
US20060204505A1
(en)
|
2005-03-08 |
2006-09-14 |
Sliwkowski Mark X |
Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
|
|
US20090061422A1
(en)
|
2005-04-19 |
2009-03-05 |
Linke Steven P |
Diagnostic markers of breast cancer treatment and progression and methods of use thereof
|
|
WO2007015935A2
(en)
|
2005-07-29 |
2007-02-08 |
Bayer Healthcare Llc |
Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy
|
|
WO2007041502A2
(en)
|
2005-09-30 |
2007-04-12 |
Monogram Biosciences |
Methods for determining responsiveness to cancer therapy
|
|
BRPI0520530A2
(pt)
|
2005-10-05 |
2009-09-29 |
Astrazeneca Uk Ltd |
método para predizer ou monitorar a resposta de um paciente a uma droga receptora do erbb
|
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
|
US7908091B2
(en)
|
2006-03-17 |
2011-03-15 |
Prometheus Laboratories Inc. |
Methods of predicting and monitoring tyrosine kinase inhibitor therapy
|
|
EP2049568A2
(en)
|
2006-04-07 |
2009-04-22 |
Københavns Universitet |
Erbb receptor-derived peptide fragments
|
|
EP2032982B1
(en)
|
2006-05-05 |
2012-08-29 |
Yale University |
Use of subcellular localization profiles as prognostic or predictive indicators
|
|
JP2009544007A
(ja)
|
2006-07-13 |
2009-12-10 |
イェール・ユニバーシティー |
バイオマーカーの細胞内局在性に基づいて癌予後を行う方法
|
|
EP2062597A4
(en)
*
|
2006-09-15 |
2010-03-03 |
Univ Tokai |
PREVENTIVE OR CLEANING AGENT FOR ER-NEGATIVE AND HER2-NEGATIVE MAMMARY CARCINOMA AND INVESTIGATION METHOD THEREFOR
|
|
US20100178651A1
(en)
|
2006-11-03 |
2010-07-15 |
Christos Hatzis |
Bifunctional Predictors of Cancer Treatment Sensitivity and Resistance
|
|
EP2518508A1
(en)
|
2006-11-28 |
2012-10-31 |
U3 Pharma GmbH |
Activated HER3 as a marker for predicting therapeutic efficacy
|
|
US7825127B2
(en)
|
2006-12-28 |
2010-11-02 |
Takeda Pharmaceutical Company, Limited |
Method for treating cancer
|
|
SG178789A1
(en)
*
|
2007-02-16 |
2012-03-29 |
Merrimack Pharmaceuticals Inc |
Antibodies against erbb3 and uses thereof
|
|
EP2899541A1
(en)
|
2007-03-02 |
2015-07-29 |
Genentech, Inc. |
Predicting response to a HER dimerisation inhbitor based on low HER3 expression
|
|
ES2529790T3
(es)
|
2007-04-13 |
2015-02-25 |
Dana-Farber Cancer Institute, Inc. |
Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB
|
|
NZ581201A
(en)
|
2007-05-11 |
2012-05-25 |
Enzon Pharmaceuticals Inc |
Rna antagonist compounds for the modulation of her3
|
|
US20090054051A1
(en)
|
2007-08-22 |
2009-02-26 |
James Cavallo |
Attachable Headset for Portable Device
|
|
BRPI0911652A2
(pt)
|
2008-04-11 |
2015-08-04 |
Merrimack Pharmaceuticals Inc |
Ligantes de albumina sérica humana e seus conjugados
|
|
WO2010019952A2
(en)
|
2008-08-15 |
2010-02-18 |
Merrimack Pharmaceuticals, Inc. |
Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
|
|
CN102282168A
(zh)
|
2008-11-18 |
2011-12-14 |
梅里麦克制药股份有限公司 |
人血清白蛋白接头以及其结合物
|
|
KR20120059568A
(ko)
|
2009-08-21 |
2012-06-08 |
메리맥 파마슈티컬즈, 인크. |
Ｅｒｂｂ３의 엑토도메인에 대한 항체 및 이의 용도
|
|
WO2011047180A1
(en)
|
2009-10-14 |
2011-04-21 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
|
|
KR101798679B1
(ko)
*
|
2010-03-11 |
2017-11-16 |
메리맥 파마슈티컬즈, 인크. |
３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
|
|
EP2564188A4
(en)
|
2010-04-26 |
2013-09-25 |
Merrimack Pharmaceuticals Inc |
TESTS FOR ANTI-MEDICATION ANTIBODIES IN THE PRESENCE OF ENDOGENOUS PROTEIN COMPOUNDS OF THE MEDICINAL PRODUCT
|
|
PH12013500064A1
(en)
|
2010-07-09 |
2013-03-11 |
Exelixis Inc |
Combinations of kinase inhibitors for the treatment of cancer
|
|
FR2963868B1
(fr)
|
2010-08-11 |
2012-09-28 |
Valeo Systemes Thermiques |
Echangeur de chaleur comprenant un element chauffant serigraphie
|
|
JP2014500278A
(ja)
|
2010-12-10 |
2014-01-09 |
メリマック ファーマシューティカルズ インコーポレーティッド |
二重特異性ｓｃＦｖコンジュゲートの投薬量および投与
|
|
CN103547598A
(zh)
|
2011-02-24 |
2014-01-29 |
梅里麦克制药股份有限公司 |
包含抗-erbb3药剂的联合治疗
|
|
BR112013022882A2
(pt)
*
|
2011-03-11 |
2016-12-20 |
Merrimack Pharmaceuticals Inc |
uso de inibidores de receptores da família egfr no tratamento de cânceres de mama hormônio-refratários
|
|
JP2014509593A
(ja)
|
2011-03-15 |
2014-04-21 |
メリマック ファーマシューティカルズ インコーポレーティッド |
ＥｒｂＢ経路阻害剤に対する耐性の克服
|
|
BR112013027021A2
(pt)
|
2011-04-19 |
2016-11-29 |
Merrimack Pharmaceuticals Inc |
anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos
|
|
JP2014514359A
(ja)
|
2011-05-06 |
2014-06-19 |
メリマック ファーマシューティカルズ インコーポレーティッド |
抗ＥｒｂＢ３剤を含む併用治療において有毒な薬物相互作用を予防するための方法
|
|
WO2012177440A1
(en)
|
2011-06-24 |
2012-12-27 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of anti-erbb3 antibodies in combination with paclitaxel
|
|
PH12013502663A1
(en)
|
2011-06-30 |
2018-03-21 |
Merrimack Pharmaceuticals Inc |
Dosage administration of anti-erbb3 antibodies in combination with paclitaxel for treatment of gynecological cancers
|
|
WO2013023043A2
(en)
*
|
2011-08-10 |
2013-02-14 |
Merrimack Pharmaceuticals, Inc. |
Treatment of advanced solid tumors using combination of anti-erbb3 immunotherapy and selected chemotherapy
|
|
EP2833915A1
(en)
|
2012-04-02 |
2015-02-11 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
|
|
WO2014036520A1
(en)
|
2012-08-30 |
2014-03-06 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-erbb3 agents
|
|
EP3087394A2
(en)
|
2013-12-27 |
2016-11-02 |
Merrimack Pharmaceuticals, Inc. |
Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
|
|
EP3107578A2
(en)
|
2014-02-20 |
2016-12-28 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
|